- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Policy Recommendations District Of Columbia
2020-21 Improvements and Recommendations
Patient enrollment in the district increased by nearly 37% between 2020 and 2021. In October of 2020, regulation of DC’s existing medical cannabis market was transferred from DC Health to the Alcoholic Beverage Regulation Administration. This is a move seen by many in the District as a pre- emptive maneuver to prepare for the long delayed adult use market to open when congress finally removes the budget limitations that have been in place since 2015.
There were new mandatory aflatoxin (mycotoxin) testing standards written into the District’s regulations; however, whoever wrote the new rule failed to establish any limits on the toxins. Effectively this means that although labs will now test for mycotoxins alongside other contaminants, there is no failure point. While DC has some of the most stringent testing requirements in place there are currently no labs licensed and accredited to operate in DC.
In 2022, ASA recommends that the DC city council pass a bill that focuses on filling the gaps that exist in their protections of civil rights for patients. Patients should not face discriminatory roadside sobriety testing. As it stands, only public employees of the district have any protection form discrimination by employers in the law, we recommend these protections are extended to all employees in all fields. The district must also keep landlords from unfairly denying patients housing or evicting them based on status. Finally, parental rights of any kind should not be denied based on a person’s status as a patient.